The objective of this study is to demonstrate that the antibacterial activity of Sudapyridine
(WX-081) is not inferior to Bedaquiline when added to a Background Regimen (BR) for treatment
of rifampicin- resistant TB. Also, safety and clinical outcome will be evaluated.